Viewing Study NCT05756166


Ignite Creation Date: 2025-12-24 @ 4:43 PM
Ignite Modification Date: 2025-12-27 @ 3:55 AM
Study NCT ID: NCT05756166
Status: TERMINATED
Last Update Posted: 2025-06-24
First Post: 2023-02-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Sponsor: Roswell Park Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module